1. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. Русская версия под общ. ред. акад. А.Г.Чучалина. Пульмонология, 1996; прил.:1 - 165.
2. Бронхиальная астма. Руководство для врачей России (формулярная система). Там же, 1999; прил.: 1-40.
3. Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Там же, 2001; 1: 65-72.
4. Формулярная система: лечение бронхиальной астмы. Астма.ru 0. 2001; 6-9.
5. Чучалин А.Г. Бронхиальная астма. М.; 1997, т.1-2.
6. Agertoft L., Pedersen S. Effect of long-term treatment with inhaled biidesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064-1069.
7. Andersson F. et al. The costs and effects of adding formoterol to budesonide - results of the FACET Study. Am. J. Respir. Crit. Care Med. 1999; 159 (3, Pt.2): A762.
8. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sei. 1993; 52: 2145-2160.
9. Ankerst J., Persson G., Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur. Respir. J. 2000; 16 (suppl.31): 33s+poster.
10. Barney P.G.J. Current questions in the epidemiology of asthma. In: Holgate S.Т., et al. Asthma: Physiology. Immunology, and Treatment. London: Academic Press; 1993. 3-25.
11. Crisholm S. et al. Once-daily budesonide in mild asthma. Respir. Med. 1998; 92: 421-425.
12. Juniper E.F., Svensson K., Byrne P.M. et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 1999; 14: 1038-1043.
13. Kips J.C., O’Connor B.J., Inman M.D. et al. A long-termed study of the antiinflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am. Respir. Crit. Care Med. 2000; 161: 996-1001.
14. McFadden E.R., Casale T.B., Edwards T.B. et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol. 1999; 104: 46-52.
15. Miller-Larsson A. et. al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162: 1455-1461.
16. Miller-Larsson A., Mattsson H., Hjertberg E., et al. Reversible fatty acid conjugation of budesonide: novel mechanism foe prolonged retention of topically applied steroid in airway tissue. Drug Metab. Dispos. 1998; 26: 623-630.
17. Molimard M. et al. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583-588.
18. O’Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the non-bronchodilatator effects of inhaled ß2-agonists in asthma. N. Engl. J. Med. 1992; 327: 1204-1208.
19. Palmquist M. et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244-249.
20. Palmquist M. et al. Inhaled dry powder formoterol and salmererol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 1997; 10: 2484-2489.
21. Pauwels R.A. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405-1411.
22. Pedersen S., O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroides in asthma. Allergy 1997; 52 (suppl.39): 1-34.
23. Politiek M.J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur. Respir. J. 1999; 13: 988-992.
24. The British Guidelines on Asthma Management. Thorax, 1997; 52 (suppl.l): 1-20.
25. Woolcock A. et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-1488.
Послать статью по эл. почте 